Filing Flows › ELI Lilly (LLY) › Capital expenditures
ELI Lilly (LLY) capital expenditures by quarter
ELI Lilly's capital expenditures were $3.2B in Q3 2026 (third quarter 2026), +8% from Q2 2026. Over the last 7 quarters it ranged from $1.5B (Q1 2025) to $3.2B (Q3 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.2B | +8% | +52% |
| Q2 2026 | $2.9B | +26% | +73% |
| Q1 2026 | $2.3B | -9% | +54% |
| Q4 2025 | $2.5B | +22% | — |
| Q3 2025 | $2.1B | +23% | — |
| Q2 2025 | $1.7B | +12% | — |
| Q1 2025 | $1.5B | — | — |
Q3 2026 at a glance
ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.
Questions
What is ELI Lilly's capital expenditures?
ELI Lilly's capital expenditures were $3.2B in Q3 2026 (third quarter 2026), +8% from Q2 2026.
How has ELI Lilly's capital expenditures changed?
Over the last 7 quarters it ranged from $1.5B (Q1 2025) to $3.2B (Q3 2026).